SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
IPO Year: 2018
Exchange: NASDAQ
Website: si-bone.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2024 | $27.00 → $19.00 | Buy | Needham |
| 3/28/2024 | $25.00 | Overweight | Piper Sandler |
| 10/12/2022 | $20.00 | Buy | Jefferies |
| 4/7/2022 | $34.00 | Overweight | Cantor Fitzgerald |
| 3/1/2022 | $30.00 → $28.00 | Overweight | Morgan Stanley |
| 1/18/2022 | $43.00 → $36.00 | Buy | B of A Securities |
| 12/21/2021 | $35.00 → $30.00 | Buy | Truist Securities |
| 11/9/2021 | $42.00 → $36.00 | Market Outperform | JMP Securities |
| 8/3/2021 | $41.00 → $40.00 | Overweight | Morgan Stanley |
| 8/3/2021 | $42.00 → $37.00 | Buy | Needham |
Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $19.00 from $27.00 previously
Piper Sandler initiated coverage of SI-BONE with a rating of Overweight and set a new price target of $25.00
Jefferies initiated coverage of SI-BONE with a rating of Buy and set a new price target of $20.00
Cantor Fitzgerald resumed coverage of SI-BONE with a rating of Overweight and set a new price target of $34.00
Morgan Stanley reiterated coverage of SI-BONE with a rating of Overweight and set a new price target of $28.00 from $30.00 previously
B of A Securities reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $36.00 from $43.00 previously
Truist Securities reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $30.00 from $35.00 previously
JMP Securities reiterated coverage of SI-BONE with a rating of Market Outperform and set a new price target of $36.00 from $42.00 previously
Morgan Stanley reiterated coverage of SI-BONE with a rating of Overweight and set a new price target of $40.00 from $41.00 previously
Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $37.00 from $42.00 previously